Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521725 | 0.74 | DRD2 (0.40) | — | |
| SCHEMBL15415293 | 0.73 | — | — | |
| SCHEMBL15415063 | 0.72 | — | — | |
| SCHEMBL9733118 | 0.71 | ALDH1A1 (0.36) | ALDH1A1SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL8371674 | 0.69 | ALDH1A1 (0.40) | ALDH1A1SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL8533863 | 0.69 | SLC6A2 (0.39) | ALDH1A1SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL15414918 | 0.68 | — | — | |
| SCHEMBL27631977 | 0.67 | ALDH1A1 (0.38) | ALDH1A1SLC6A2ADRA1AHTR2BSLC6A3 | |
| SCHEMBL16619789 | 0.67 | HRH4 (0.39) | ALDH1A1SLC6A2SLC6A3 | |
| SCHEMBL2146147 | 0.67 | PARP1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110123820-B | Arginase inhibitors and methods of use thereof | 阿斯利康公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-112805067-A | Indole and azaindole inhibitors of PAD enzymes | 百时美施贵宝公司 | 2021-05-14 | — | — | CN | disclosed |
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2020-07-16 | — | — | US | disclosed |
| EP-2389352-B1 | ARGINASE INHIBITORS AND METHODS OF USE | UNIV PENNSYLVANIA (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20190127395-A1 | Arginase Inhibitors and Methods of Use | ASTRAZENECA AB (SE) | 2019-05-02 | — | — | US | disclosed |
| US-10118936-B2 | Arginase inhibitors and methods of use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180271809-A1 | USE OF NICLOSAMIDE IN THE TREATMENT OF P53-DEFICIENT CELLS | AGENCY FOR SCIENCE, TECHOLOGY AND RESEARCH (SG) | 2018-09-27 | — | — | US | disclosed |
| EP-3349742-A1 | USE OF NICLOSAMIDE IN THE TREATMENT OF P53-DEFICIENT CELLS | Agency For Science, Technology And Research (SG) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017048197-A1 | USE OF NICLOSAMIDE IN THE TREATMENT OF P53-DEFICIENT CELLS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-03-23 | — | — | WO | disclosed |
| US-20160194340-A1 | ARGINASE INHIBITORS AND METHODS OF USE | UNIV PENNSYLVANIA (US) | 2016-07-07 | — | — | US | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050143394-A1 | Phenylpiperazine cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005037807-A1 | ARYLALKYL- AND CYCLOALKYLALKYL-PIPERAZINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037808-A1 | PHENYLPIPERAZINE CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037207-A2 | ARYLALKYL-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE INCLUDING VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037279-A1 | 1- 2’ (1, 4’-BIPERIDIN-1’-YL)-1- (PHENYL) -ETHYL CYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VISOMOTOR SYMPTOMS | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20050085472-A1 | Pyrazolo pyrimidine derivatives and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-04-21 | — | — | US | disclosed |
| WO-2005007085-A2 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-01-27 | — | — | WO | disclosed |
| CN-1450915-A | Matrix metalloproteinase inhibitors as target components in diagnostic agents | BRISTOL MYERS SQUIBB CO (US) | 2003-10-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | HTR3A, MAOA, FAAH | ALDH1A1 445/4885SLC6A2 125/4885ADRA1A 51/4885 |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | ALDH1A1 244/4885SLC6A2 108/4885ADRA1A 140/4885 |
| US-20180271809-A1 | USE OF NICLOSAMIDE IN THE TREATMENT OF P53-DEFICIENT CELLS | TP53, NCSTN, TP53BP1 | ALDH1A1 628/4885SLC6A2 3438/4885ADRA1A 4860/4885 |
| US-20050085472-A1 | Pyrazolo pyrimidine derivatives and methods of use thereof | DPYD, DHODH, DLD | ALDH1A1 198/4885SLC6A2 2350/4885ADRA1A 2674/4885 |
| US-20200223871-A1 | Arginase Inhibitors and Methods of Use | ARG1, ARG2, NOS2 | ALDH1A1 407/4885SLC6A2 862/4885ADRA1A 1482/4885 |
| US-10118936-B2 | Arginase inhibitors and methods of use | ARG1, ARG2, NOS2 | ALDH1A1 407/4885SLC6A2 862/4885ADRA1A 1482/4885 |
| US-20160194340-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, NOS2 | ALDH1A1 407/4885SLC6A2 862/4885ADRA1A 1482/4885 |
| US-20190127395-A1 | Arginase Inhibitors and Methods of Use | ARG1, ARG2, NOS2 | ALDH1A1 407/4885SLC6A2 862/4885ADRA1A 1482/4885 |
| US-20050143394-A1 | Phenylpiperazine cycloalkanol derivatives and methods of their use | HTR5A, PNMT, HTR3A | ALDH1A1 1206/4885SLC6A2 49/4885ADRA1A 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.